Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06652087 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Rifaximin and Cardiac Function in Patients with Heart Failure with Preserved Ejection Fraction

Study acronym: SIBO-HFpEF
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 22, 2024 (before its estimated September 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
Single-center, double-blind, randomized, controlled intervention study of the effect of correction of bacterial overgrowth syndrome in the small intestine (SIBO) on cardiac function in patients with heart failure with preserved ejection fraction (HFpEF) (SIBO-HFpEF). The aim of the study is to evaluate the efficacy and safety of rifaximin in patients with HFpEF and SIBO.
Trial Details
NCT Number NCT06652087
Lead Sponsor I.M. Sechenov First Moscow State Medical University
Conditions
(from sponsor)		 Bacterial Overgrowth Syndrome Small Bowel, Heart Failure with Preserved Ejection Fraction
Related terms Obesity, Overweight
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov